by Plus Therapeutics | Apr 8, 2025 | GBM, LM, PBC, Uncategorized
The Power of Radionuclide-Based Therapies in Modern Cancer Treatment Radionuclide-based therapies represent a rapidly evolving frontier in precision oncology, offering targeted treatment options for a wide range of cancer types. These therapies utilize radionuclides...
by Plus Therapeutics | Apr 2, 2025 | GBM, LM, PBC, Uncategorized
A Novel Radiotherapeutic Platform Targeting Complex Tumors with Precision At Plus Therapeutics, we’re pioneering a next-generation radiotherapeutic platform designed to deliver targeted cancer treatment with high precision and minimal toxicity. Our platform is powered...
by Plus Therapeutics | Mar 26, 2025 | GBM, LM, PBC, Uncategorized
REYOBIQ™: A Promising Radiotherapeutic Advancing Treatment for Glioblastoma, Leptomeningeal Metastases, and Pediatric Brain Cancers At Plus Therapeutics, we’re advancing the future of cancer care with REYOBIQ™ (rhenium-186 Re obisbemeda), our lead targeted...
by Plus Therapeutics | Mar 20, 2025 | GBM, LM, PBC, Uncategorized
Introducing REYOBIQ™: The FDA-Accepted Proprietary Name for Plus Therapeutics’ Lead Drug Candidate Big News from Plus Therapeutics! The U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name REYOBIQ™ (rhenium Re186 obisbemeda) for our...
by Plus Therapeutics | Feb 28, 2025 | GBM, LM, PBC, Uncategorized
Shining a Light on Rare Diseases: Raising Awareness Together At Plus Therapeutics, we are committed to advancing research and innovative treatments for rare and challenging diseases. Today, on Rare Disease Day, we stand with patients, caregivers, and advocates...
by Plus Therapeutics | Feb 20, 2025 | GBM, LM, PBC, Uncategorized
Plus Therapeutics Appoints Michael Rosol, Ph.D., as Chief Development Officer We are excited to announce the appointment of Michael Rosol, Ph.D., as Chief Development Officer at Plus Therapeutics. In this role, Dr. Rosol will oversee the company’s clinical,...
Recent Comments